Infliximab effect on serum IGF-1 and IGFBP-3 in active inflammatory bowel disease
Year: 2005
Type: article
Abstract: SUMMARY AIM: There are few studies that have investigated the changes of the insulin-like growth factor (IGF) system in inflammatory bowel disease (IBD) and the majority of these studies have examined the alterations of the GH-IGF axis in growth-retarded IBD children. Moreover, the impact of the chimeric monoclonal anti-TNFAE antibody (Infliximab) in the IGF system in patients with Crohnis disease (CD) or ulcerative colitis (UC) has not yet been investigated. PATIENTS-METHOD: Five IBD patients (3 with Crohnis and 2 with ulcerative colitis) and five age and sex matched controls were included in this study. In all patients and controls a baseline serum sample for IFG-1, IGFBP-3 and IL-6 was obtained one week before Infliximab treatment initiation. During the first four times of Infliximab administration morning fasting serum samples were obtained from each patient. At the same time, fasting morning control samples were also obtained. RESULTS: Short-term effect of infliximab administration (baseline-1 st
Source: Annals of Gastroenterology
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2188644088